Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma

Publication date: August 2018

Source: Cancer Epidemiology, Volume 55

Author(s): Noah C. Peeri, Jordan H. Creed, Gabriella M. Anic, Reid C. Thompson, Jeffrey J. Olson, Renato V. LaRocca, Sajeel A. Chowdhary, John D. Brockman, Travis A. Gerke, L. Burton Nabors, Kathleen M. Egan

Abstract

Background

Selenium is an essential trace element obtained through diet that plays a critical role in DNA synthesis and protection from oxidative damage. Selenium intake and polymorphisms in selenoproteins have been linked to the risk of certain cancers though data for glioma are sparse.

Methods

In a case-control study of glioma, we examined the associations of selenium in toenails and genetic variants in the selenoenzyme pathway with the risk of glioma and patient survival. A total of 423 genetic variants in 29 candidate genes in the selenoenzyme pathway were studied in 1547 glioma cases and 1014 healthy controls. Genetic associations were also examined in the UK Biobank cohort comprised of 313,868 persons with 322 incident glioma cases. Toenail selenium was measured in a subcohort of 300 glioma cases and 300 age-matched controls from the case-control study.

Results

None of the 423 variants studied were consistently associated with glioma risk in the case-control and cohort studies. Moreover, toenail selenium in the case-control study had no significant association with glioma risk (p trend = 0.70) or patient survival among 254 patients with high grade tumors (p trend = 0.70).

Conclusion

The present study offers no support for the hypothesis that selenium plays a role in the onset of glioma or patient outcome.

https://ift.tt/2lUhRtx